Acute opioid withdrawal is associated with increased neural activity in reward-processing centers in healthy men: A functional magnetic resonance imaging study  by Chu, Larry F. et al.
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Background: Opioid analgesics are frequently prescribed for chronic pain. One expected consequence
of long-term opioid use is the development of physical dependence. Although previous resting state
functional magnetic resonance imaging (fMRI) studies have demonstrated signal changes in reward-
associated areas following morphine administration, the effects of acute withdrawal on the human brain
have been less well-investigated. In an earlier study by our laboratory, ondansetron was shown to be
effective in preventing symptoms associated with opioid withdrawal. The purpose of this current study
was to characterize neural activity associated with acute opioid withdrawal and examine whether these
changes are modiﬁed by ondansetron.
Methods: Ten participants were enrolled in this placebo-controlled, randomized, double-blind, crossover
study and attended three acute opioid withdrawal sessions. Participants received either placebo or
ondansetron (8mg IV) before morphine administration (10mg/70kg IV). Participants then underwent
acute naloxone-precipitatedwithdrawal during a resting state fMRI scan. Objective and subjective opioid
withdrawal symptoms were assessed.
Results: Imaging results showed that naloxone-precipitated opioid withdrawal was associated with
increased neural activity in several reward processing regions, including the right pregenual cingulate,
putamen, and bilateral caudate, and decreased neural activity in networks involved in sensorimotor inte-
gration. Ondansetron pretreatment did not have a signiﬁcant effect on the imaging correlates of opioid
withdrawal.
Conclusions: This study presents a preliminary investigation of the regional changes in neural activity
during acute opioidwithdrawal. The fMRI acute opioidwithdrawalmodelmay serve as a tool for studying
opioid dependence and withdrawal in human participants.
rs. Pu© 2015 The Autho
. Introduction
Opioid medications are frequently prescribed for pain relief,
ncluding as a long-term treatment for chronic pain. When given
ver time, physical dependence can occur. If opioid medications
re abruptly stopped, unpleasant withdrawal effects, such as agi-
ation and nausea, are often experienced. Changes in mood, such
s increased anxiety, are also an expected part of opioid with-
rawal. The objective and subjective signs and symptoms of opioid
ithdrawal are well-documented, and validated scales have been
∗ Corresponding author. Tel.: +1650 723 6632.
E-mail address: lchu@stanford.edu (L.F. Chu).
ttp://dx.doi.org/10.1016/j.drugalcdep.2015.04.019
376-8716/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).blished by Elsevier Ireland Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
developed for their assessment (Handelsman et al., 1987). While
objective changes during opioid withdrawal (e.g., mydriasis and
piloerection) are simple to observe, relatively little is known about
the neural changes associated with subjective experience of with-
drawal. A better understanding of withdrawal-related changes
in brain functioning may allow us to more effectively combat
withdrawal effects, and perhaps even prevent some forms of
dependence.
Resting state functional magnetic resonance imaging (fMRI) is
a method for evaluating changes in brain activity that occur when
a participant is not performing an explicit task. The approach can
provide a non-invasive method of characterizing the acute neu-
ropharmacological effects of drugs. Resting state fMRI relies on
low-frequency ﬂuctuations in blood oxygen that are presumed to
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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epresent changes in neural activity. The resulting blood oxygen
evel-dependent (BOLD) signal provides an endogenous image con-
rast that allows active brain regions to be distinguished from less
ctive ones.
In pharmacologic fMRI studies of drugs that do not have ultra-
ast half-lives, it is often impossible to use a task-related design.
nstead, long, taskless, timeseries data must be analyzed. Taskless
esigns (often referred to as “resting-state” designs) preclude tradi-
ional fMRI analytic techniques inwhicha canonizedhemodynamic
esponse pattern is convolved with the task timeline. Interpre-
ation of the BOLD signal can be difﬁcult in such cases. Seed- or
etwork-based analyses can be conducted, but there is insufﬁcient
nformationonnetworks involved inopioidprocesses in thehuman
rain. For those reasons, it may be more informative to examine
ow frequency oscillations (LFO), which can be considered a poten-
ial index of spontaneous ﬂuctuations at rest. Previous fMRI studies
nvestigating LFOamplitudeshave reportedmeaningful differences
mong brain regions and clinical populations (Hoptman et al.,
010; Zang et al., 2007). An approach called amplitude of low fre-
uency ﬂuctuations (ALFF) provides a measure of regional changes
n neural activity in a resting state scan (Zang et al., 2007). ALFF
nalyzes signal ﬂuctuations in a range associatedwith neural activ-
ty (0.01–0.08Hz), only considering frequencies lower than those
ttributed to cardiac motion and respiration (approximately 1Hz
nd 0.2–0.3Hz, respectively) (Wang et al., 2008). Previous research
as shown that ALFF results correlate reliably with cerebral blood
ow (Li et al., 2012). ALFF provides clusters of BOLD-signal change
hat can be interpreted in the same way as traditional task-related
OLD analyses.
The selective serotonin (5-HT)3 receptor antagonist
ndansetron has been shown to decrease nausea and vomiting
ollowing exposure to opioid, anesthetic, and chemotherapeutic
edications (Kaasa et al., 1990; Leeser and Lip, 1991; Rung
t al., 1997). Animal evidence provides additional support for
he notion that ondansetron can prevent signs of opioid with-
rawal. Roychoudhury and Kulkarni (1996) found that 0.1mg/kg
ndansetron prevented naloxone-induced opioid withdrawal in
ice, and similar ﬁndings have been observed in rats (Hui et al.,
996; Pinelli et al., 1997). Previous work from our laboratory
xploring genetic data on inbred strains of mice revealed that the
ene most strongly associated with withdrawal severity was that
or the 5-HT3 receptor that is targeted by ondansetron. Further-
ore, the animal data also show that blockadeof this receptor leads
o a reduction in withdrawal-related behavior (Chu et al., 2009).
ndansetron has likewise been shown to ease or prevent objective
pioid-withdrawal symptoms in healthy humans given morphine
xperimentally (Chu et al., 2009). This model for assessing acute
pioid-withdrawal effects has be shown to be safe and effective in
roducing acute opioid withdrawal in healthy men, and has been
tilized in previous publications (Compton et al., 2003, 2004).
The primary purpose of the current study was to characterize
hanges in brain activity associated with acute opioid withdrawal
sing fMRI. Based on evidence from animal and human studies, it
as hypothesized that changes in neural activity, manifested as
hanges in ALFF, would be observed in the reward-related regions.
secondary aim was to examine whether withdrawal-related
hanges in brain activity could be modiﬁed by pretreatment with
ndansetron.
. Materials and methods.1. Participants
Fifteen healthy male volunteers were enrolled in this ran-
omized, double-blinded, placebo-controlled crossover study.endence 153 (2015) 314–322 315
Participants were excluded on the basis of (1) regular medication
use; (2) a history of substance use, including cannabis and nico-
tine, as well as opioid use within the last 12 months; (3) Raynaud’s
Disease or Coronary Artery Disease; and (4) MRI contraindications.
Female participantswere not recruited for this study becausemen-
strual cycles can alter the opioid response (Hoehe, 1988).
The Institutional ReviewBoard (StanfordUniversity) authorized
the human experimental protocol on April 15th, 2009, and the
study was part of a larger study that was registered in the clini-
caltrials.gov database (identiﬁer NCT01006707). Written informed
consentwas obtained fromall participants before this researchwas
undertaken.
2.2. Overall study protocol
The protocol used for opioid-induced withdrawal has been pre-
viously described (Compton et al., 2003). During this study, each
participant attended three separate laboratory-based acute opioid
withdrawal sessions. The ﬁrst session was undertaken in a mock
MRI scanner and was designed to determine if participants could
toleratewithdrawal in the scanning environment. Participantswho
were able to successfully and safely tolerate opioid withdrawal
while in the scanner were approved to continue with the following
study sessions.
Participants were pretreated intravenously (IV) with either
0.9% normal saline placebo or 8mg ondansetron prior to IV mor-
phine (10mg/70kg). Later, participants in all sessions received IV
naloxone (10mg/70kg) to precipitate opioid withdrawal. In the
mock MRI session, all participants received placebo pretreatment.
In the two subsequent sessions, participants were assigned to
ondansetron or placebo pretreatment conditions in a randomized
(double-blinded) and counter-balanced order. All study sessions
were conducted by a blinded research assistant (AC, JS, DH, HA)
and supervised by an unblinded physician (LC) who administered
the study medication and monitored participants throughout the
study. The three separate study sessions for each participant were
scheduled at least one week apart.
2.3. Study session timeline
Fig. 1 outlines the study session timeline; the time of naloxone
administration is marked as T=0. Prior to the MRI, ondansetron or
saline placebo was administered as an IV bolus at T=−165. Thirty
minutes later, T=−135, morphine was administered as an infusion
over10min. Participants remained in the labunderobservationand
were offered music or video entertainment and caffeine-free meals
or snacks ad lib until they were transported to the MRI scanner.
The MRI scan commenced at T=−41, and high-resolution struc-
tural scan was acquired. Acquisition of resting state data began
at T=−9, and at T=0, naloxone was administered as an IV bolus.
Scanning continued for a further 15min and then participants
were removed from the scanner. The total study session time was
185min.
2.4. Objective and subjective opioid withdrawal symptoms
The Objective Opioid Withdrawal Scale (OOWS) and Sub-
ject Opioid Withdrawal Scale (SOWS) ratings – validated by
Handelsman et al. (1987) – were used during study sessions to
assess withdrawal symptoms and possible modulation of opioid
withdrawal by ondansetron. The OOWS consists of 13 observable
physical symptoms that are assessed over a ﬁve-minute observa-
tion period and scored as present (score of 1) or absent (score of
0). The total OOWS score is determined by summing scores for the
13 physical symptoms. Lacrimation and mydriasis were unable to
be assessed during the eyes-closed resting state scan and were
316 L.F. Chu et al. / Drug and Alcohol Dependence 153 (2015) 314–322
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iig. 1. (A) Overall study session timeline depicting ondansetron/placebo adminis
ymptoms. (B) Timeline of the MRI scan showing resting state acquisition, and the
herefore excluded from overall OOWS score calculations at all
ime points. All OOWS measurements were obtained by the same
linded research assistant during the study. The SOWS consists of
6 physical and emotional symptoms that are rated by the partici-
ant on a scale from 0 (not at all) to 4 (extremely), to indicate the
xtent to which the symptom describes how they are feeling at the
ime. Similarly, the total SOWS score is determined by summing
he scores of the 16 items (Handelsman et al., 1987).
OOWS and SOWS were assessed T=−13 and these were treated
s baseline scores. OOWS were repeated by a research assistant in
he scan room at two time points after naloxone administration –
=5 and T=152. SOWS were not assessed during the resting state
can as participants were asked to remain still during the scan;
t T=20min, participants were asked to reﬂect on the withdrawal
eriod (at T=15) in order to assess their SOWS score.
.5. Physiological monitoring
Physiological data were recorded using the Medrad Veris MR
hysiologic monitoring system (Bayer Healthcare, Berkeley, CA).
eart rate and arterial oxygenation were monitored by a physician
hroughout the study.Measurements taken at the same timepoints
s OOWS (T=−13 and T=15) were examined during analysis.
.6. MRI data acquisition
Data were collected at the Richard M. Lucas Center for Imaging
t Stanford University, using a 3.0 T GE Healthcare Discovery 750
GE Signa, Milwaukee, WI) and an 8-channel head coil. Resting-
tate functional bloodoxygen level-dependent (BOLD) imageswere
cquired with a T2*-sensitive spiral in/out pulse sequence (Glover
nd Law, 2001) and the following parameters: TR=2000ms,
E =30ms, FOV=220mm, in-plane resolution=3.4×3.4mm, ﬂip
ngle =76◦, 31 slices, slice thickness =4.0mm, 0.5mm gap, scan
uration=24min. Higher order shimming was performed prior
o the scan (Kim et al., 2002). During the scan, participants were
xplicitly instructed to keep their eyes closed, relax, and move as
ittle as possible. A high resolution T1-weighted 3D-IR-FSPGR scan
as also acquired for anatomical reference – TE=2.2ms, 128 slices,
n-plane resolution=0.86×0.86mm, slice thickness =1.2mm.n, morphine infusion, and assessment of objective/subjective opioid withdrawal
st blocks included in analysis.
2.7. Function data processing
Prior to preprocessing, the ﬁrst four volumes were discarded
to allow for scanner stabilization and for participants to adapt to
the environment. Datawere then preprocessed usingData Process-
ing Assistant for Resting State fMRI (DPARSF; State Key Laboratory
of Cognitive Neuroscience and Learning, Beijing Normal Univer-
sity, China; Yan and Zang, 2010), which includes the RESTing-state
fMRI data analysis Toolkit (REST; Song et al., 2011). Both toolboxes
work on the basis of SPM8 (Wellcome Trust Centre for Neuroimag-
ing, London, UK) within MATLAB. Raw data were separated into
pre- and post-naloxone blocks, each consisting of 266 volumes
(8min 52 s) from the beginning and end of the scan, respectively.
This enabled the comparison of balanced pre- and post-naloxone
blocks, and avoided the inclusionof images contaminatedbymove-
ment artifacts associated with drug administration. See Fig. 2 for a
representative BOLD timecourse. Images were then corrected for
within-scan acquisition time differences between slices, motion-
corrected using a least-squares approach and a six-parameter
(rigid body) linear transformation, spatially normalized to Mon-
treal Neurological Institute (MNI) space, and smoothed by a 4mm
full-width-at-half-maximum Gaussian kernel to yield a voxel size
of 3×3×3mm (Sacchet and Knutson, 2013). The data were then
linearly detrended and bandpass ﬁltered (0.01–0.08Hz) to reduce
low-frequency drift and high-frequency physiological noise. No
participants had head motion greater than 1.5mm translation or
1.5◦ rotation in any direction.
2.8. Statistical analysis
2.8.1. General statistical methods. Vital signs (heart rate and
oxygen saturation levels) OOWS data were analyzed using
a doubly repeated measures analysis of variance (rmANOVA)
with two within-subjects factors: pretreatment (placebo versus
ondansetron) and time (baseline, T=5, and T=15). SOWS data
also used the rmANOVA with pretreatment (placebo versus
ondansetron) and time (baseline and T=15). Main and interaction
effects were assessed. Posthoc pairwise contrasts were performed
with least signiﬁcant differences. Planned contrasts (paired t-tests)
were also performed between pretreatment sessions at T=5 and
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Fig. 2. Example of ALFF signal change before and after naloxone administration. The blood-oxygen-level dependent (BOLD) timecourse over the entire functional scan is
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aloxone administration. BOLD amplitude ﬂuctuation is decreased after naloxone a
= 15 for the OOWS, and T=20 for the SOWS. Results were consid-
red signiﬁcant at p<0.05.
.8.2. Imaging statistical methods. ALFF data were examined with
n rmANOVA in SPM8 using a mixed effects model. Participant was
random factor and the model had two within-subjects factors:
ime (pre-naloxone, post-naloxone) and pretreatment (placebo,
ndansetron). Voxelwise analysis was conducted using a signiﬁ-
ance threshold of p<0.0001 (uncorrected) that corresponded to
false discovery rate of 0.01. A separate cluster threshold of ﬁve
oxels was also used. The ﬁve-voxel spatial threshold meant that
cluster must be at least 135mm3 to be considered signiﬁcant.
ll main and interaction effects were assessed. ALFF signal changes
ithin signiﬁcant clusters were also tested (two-tailed) for asso-
iations with change in OOWS and SOWS scores between baseline
nd T=15 and T=20, respectively, using Spearman’s rho (rs).
. Results.1. Participants
Three participants were unable to tolerate withdrawal in the
canning environment. Two additional participants were lost to
ig. 3. (A) Objective opioidwithdrawal scale (OOWS) score and (B) subjective opioidwithd
ithdrawal in placebo and ondansetron sessions. Error bars represent 95% conﬁdence intxel from the left postcentral gyrus, the region showing the greatest change after
stration.
follow-up after the ﬁrst session. Therefore, 10 participants aged
21–34 (mean 27.1±4.3 years) completed the protocol and were
included in the ﬁnal analyses.
3.2. Physiological data
There was a non-signiﬁcant main effect of pretreatment on
heart rate (F(1,7) = 5.296, p=0.055)with higher heart rate observed
in the ondansetron pretreatment group (64.7 vs 72.9 bpm). How-
ever, the model did not yield a signiﬁcant main effect for time
(F(2,6) = 1.189, p=0.367). The time×pretreatment interaction was
not signiﬁcant (F(2,6) = 2.665, p=0.148). There were no signiﬁ-
cant main effects of pretreatment (F(1,7) = 0.184, p=0.681), time
(F(2,6) = 1.600, p=0.277) or interactions (F(2,6) = 0.356, p=0.714)
associated with arterial oxygenation.
3.3. Opioid withdrawal symptoms
OOWS. There was a signiﬁcant main effect of time on OOWS
scores (F(2,8) = 8.10, p=0.012) with objective withdrawal symp-
toms increasing after naloxone administration (Fig. 3A). Post-hoc
analyses showed that OOWS scores at T=15 were signiﬁcantly dif-
ferent from both baseline (p=0.002) and T=5 (p=0.024). OOWS
rawal scale (SOWS) scores over time before and after naloxone-precipitated opioid
ervals.
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cores at baseline and T=5 did not differ signiﬁcantly (p=0.121).
he model did not yield a signiﬁcant main effect for pretreatment
F(1,9) = 3.14, p=0.110). The time×pretreatment interaction was
ot signiﬁcant (F(2,8) = 1.17, p=0.358).
Planned contrasts at T=5 yielded a signiﬁcant difference in
OWS scores between sessions (1±0.5 vs. 2±1.3, p=0.042). In
he ondansetron session, participants did not exhibit signs of
ithdrawal at T=5. There was no between session difference at
=15 (2.7±1.1 vs. 2.2±1.1, p=0.322). Participants exhibited signs
f withdrawal at T=15, but ondansetron administration did not
ppear to suppress withdrawal symptoms.
SOWS. There was a signiﬁcant main effect of time on SOWS
cores (F(1,9) = 19.25, p=0.002), with subjective withdrawal symp-
oms increasing after naloxone administration (Fig. 3B). There
as no signiﬁcant main effect for pretreatment (F(1,9) = 1.36,
= 0.274). The time×pretreatment interaction was not signiﬁcant
F(1,9) = 0.112, p=0.315).
Planned contrasts revealed no signiﬁcant differences in SOWS
etween sessions at T=20 (5.7±4.5 vs 8.1±7.2, p=0.261).
.4. Imaging resultsFirst, the main effect of naloxone administration was tested,
ontrasting the baseline period with the withdrawal period in
ll participants and sessions. Main effects in the ALFF signal
ere found in multiple cortical and subcortical regions (Table 1).
ig. 4. Changes in neural activity associated with naloxone administration. Signiﬁcant cl
onvention is used. Left to right—coronal, axial, and sagittal views (x=21, y=15, z=3) s
recipitated withdrawal. Increases in ALFF were observed in the middle and inferior fron
n ALFF were observed in the postcentral gyrus, superior temporal gyrus, and cuneus.
ig. 5. Areas of altered neural activity represented on a 3D brain rendering. Areas of decrendence 153 (2015) 314–322
Increased neural activity was observed in several reward- and
affect-processing regions, including the right pregenual cingulate,
right putamen, and bilateral caudate head (Fig. 4). Other regions
withneural activity increaseswere the inferior,medial andsuperior
frontal gyri, right gyrus rectus, and the fusiform gyrus.
Several regions showed decreased ALFF signal after naloxone
administration. Those regions included the left postcentral gyrus
(Fig. 5), left visual associative area, left precuneus, left cuneus, bilat-
eral posterior insula, and superior temporal gyrus.
The contrast for main effects of session (placebo versus
ondansetron) did not yield any signiﬁcant clusters. Also, the
time×pretreatment interaction did not yield any signiﬁcant clus-
ters.
Of the regions showing ALFF change after naloxone administra-
tion, several showed signiﬁcant changes in ALFF signal that were
associated with some OOWS or SOWS scores. Increased neural
activity was positively correlated with greater change in OOWS
within the bilateral inferior frontal gyri (Fig. 6), and with change in
SOWS within the right middle frontal gyrus (orbital), right superior
frontal gyrus (medial), left caudate head, and right lobuleVIIB in the
cerebellum. Decreased neural activity was negatively correlated
with increased OOWS in the left superior temporal gyrus.4. Discussion
While we are not aware of a previous fMRI study examining
the neural correlates of acute opioid withdrawal in the human
usters are shown on an MNI-normalized T1 template. Neurological (right on right)
howing areas of ALFF increase (red) and decrease (blue-green) during naloxone-
tal gyri, pregenual cingulate, right putamen, and bilateral caudate head. Decreases
eased ALFF were observed in bilateral precentral and postcentral gyri (green).
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Table 1
Regions showing signiﬁcant increases or decreases in ALFF associated with naloxone administration.
Region MNI coordinates T Voxels rs (p) OOWS rs (p) SOWS
Regions with increased ALFF
Frontal lobe
Right gyrus rectus (BA 11) 9, 30, −21 5.78 5 0.410 (0.091) 0.115 (0.649)
Right inferior frontal gyrus, opercular 60, 12, 6 5.35 10 −0.255 (0.308) −0.372 (0.129)
Left inferior frontal gyrus, orbital −45, 45, −15 6.65 14 0.519 (0.027) 0.328 (0.184)
Right inferior frontal gyrus, orbital 39, 57, −9 5.09 53 0.562 (0.015) 0.486 (0.041)
Right middle frontal gyrus 42, 54, 3 6.89 13 0.261 (0.296) 0.305 (0.218)
Right superior frontal gyrus, medial 3, 48, 3 5.78 16 0.278 (0.264) 0.478 (0.045)
9, 66, 21 6.38 12 0.069 (0.785) 0.224 (0.371)
Temporal lobe
Left fusiform gyrus −51, −18, −30 5.94 6 0.195 (0.438) 0.402 (0.098)
Right middle temporal gyrus 60, −24, −18 6.44 15 0.047 (0.785) 0.049 (0.847)
Subcortical gray structures
Left caudate head −12, 15, 0 8.85 75 0.448 (0.062) 0.475 (0.047)
Right caudate head 18, 18, 3 4.92 21 0.167 (0.507) 0.005 (0.984)
Right putamen 30, 9, −6 5.41 7 0.440 (0.068) −0.08 (0.974)
Medial paralimbic cortices
Right pregenual cingulate (BA 10) 12, 48, 12 6.43 10 0.202 (0.421) 0.120 (0.634)
Cerebellum
Left crus II −27, −81, −45 6.61 20 0.136 (0.590) −0.059 (0.816)
−45, −63, −45 5.90 5 0.106 (0.674) −0.234 (0.351)
Right lobule VIIB 30, −75, −48 5.48 5 0.430 (0.075) −0.061 (0.809)
39, −57, −45 5.10 5 0.388 (0.112) 0.596 (0.009)
Left lobule VI −24, −63, −30 6.62 15 0.124 (0.625) −0.143 (0.571)
Regions with decreased ALFF
Parietal lobe
Left pre/postcentral gyrus (BA 21/22) −36, −21, 48 −10.44 1109 −0.301 (0.224) −0.225 (0.369)
Left precuneus −6, −45, 60 −5.23 7 −0.165 (0.513) −0.152 (0.548)
−9, −42, 48 −6.41 10 −0.434 (0.072) −0.250 (0.317)
Temporal lobe
Left posterior insula −36, −18, 18 −7.58 14 −0.265 (0.288) −0.180 (0.476)
Right posterior insula 33, −21, 21 −5.51 9 −0.029 (0.910) −0.089 (0.725)
Left superior temporal gyrus −57, −36, 6 −8.43 22 −0.612 (0.007) −0.354 (0.149)
Right superior temporal gyrus 63, −15, 9 −6.80 16 −0.229 (0.361) −0.255 (0.306)
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Left cuneus (calcarine) −6, −93, 15
Left visual associative area (BA 18) −9, −69, 3
rain, several related studies have been conducted. A previous fMRI
tudy examined the effects of morphine administration in opioid-
aive healthy volunteers and observed positive signal changes
n reward-related structures, including the nucleus accumbens,
mygdala, orbitofrontal cortex, and hippocampus (Becerra et al.,
006). Another study showed that administration of the mu-
pioid antagonist naloxone to healthy volunteers (not on an opioid
gonist) was associated with signal changes in the perigenual cin-
ulate, insula, hippocampus, and entorhinal cortex, regions known
o contain high levels of mu-opioid receptors (Borras et al., 2004).
nimal models of acute opioid withdrawal have demonstrated
lterations in glucose metabolism (Geary and Wooten, 1987) as
ell as BOLD signal changes in the entorhinal, cingulate, insular,
ig. 6. (A) Sagittal view (x=−15) of ALFF signal increase in the bilateral inferior frontal gyr
nd right middle temporal gyrus also pictured. (B) Scatterplots showing the relationship
y-axis) in the left inferior frontal gyrus and (C) right inferior frontal gyrus..12 72 −0.135 (0.593) −0.063 (0.803)
.34 11 −0.237 (0.343) −0.246 (0.325)
visual, and auditory cortices, and the dentate gyrus of the hip-
pocampus (Lowe et al., 2002). Those previous studies show that
fMRI can be used to assess opioid-relevant processes in the brain.
In this study, several regional changes in neural processing
associated with acute opioid withdrawal in healthy human par-
ticipants were observed, suggesting that fMRI can be used to
explore acute withdrawal in humans. To our knowledge, this study
represents the ﬁrst resting-state fMRI examination of acute opi-
oid withdrawal in healthy humans. Individuals pretreated with
IV morphine were administered IV naloxone while undergoing a
functional neuroimaging scan. Naloxone administration resulted in
both neural activity increases and decreases, as measured by sig-
nal ﬂuctuations in the 0.01–0.08Hz range. Naloxone-precipitated
i (circled). Neurological (right on right) convention is used. Clusters in the left insula
between change in objective withdrawal scores (x-axis) and ALFF signal increase
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ithdrawal was associated with increased neural activity mainly
n anterior reward-processing brain regions. Decreased activity
as seen mainly in posterior, sensorimotor aspects of the brain.
ndansetron pretreatment had no observable effect onwithdrawal
ymptoms assessed 15min following naloxone administration, or
n the neural response to naloxone. Themajor ﬁndings, limitations,
nd suggested future research will now be discussed.
.1. Major ﬁndings: Effects of naloxone-precipitated withdrawal
n resting state activity
The primary aim of this study was to assess the neural
orrelates of naloxone-precipitated withdrawal. Naloxone admin-
stration was associated with increased neural activity in several
eward-association and reward-prediction regions of the brain,
uch as the caudate, pregenual cingulate, orbitofrontal gyrus, mid-
le orbital gyrus, and putamen. Because activity in these regions
ave been previously associated with the processing of reward
ues (e.g., Staudinger et al., 2011; Langleben et al., 2014), we
xpected that naloxone would signiﬁcantly decrease neural activ-
ty as the morphine is displaced and rewarding opioid processes
eased. However, the present results are consistent with previ-
us animal research that shows glucose metabolism is elevated in
eward-processing regionsduringnaloxonewithdrawal (Gearyand
ooten, 1987). Furthermore, limited fMRI andPEThuman research
hows that morphine administration acutely decreases activity in
he same reward-processing regions (Khalili-Mahani et al., 2012;
ondon et al., 1990).
Several areas of neural activity decreases were observed in
etworks involved in sensorimotor integration. The effects were
ypically seen bilaterally. The strongest effectwas observed in clus-
ers encompassing the bilateral precentral and postcentral gyri.
eural activity decreases were also observed in the bilateral poste-
ior insula, a region identiﬁedasakey seatofnetworkdysregulation
n opioid-dependent individuals (Upadhyay et al., 2010). Decreases
n the left anterior precuneus, just superior to the posterior cingu-
ate (BA 31) were also observed. Finally, activity was decreased in
he bilateral temporal lobe, on the boundary between the middle
nd superior temporal gyri (BA 21 and 22), though leaning heavily
o the superior gyri. Several studieshave linked theposterior insula,
nterior precuneus, and postcentral gyrus to a larger network asso-
iated with attentional monitoring of the body (Cauda et al., 2011;
hangandLi, 2012). It is not clearhowacuteopioidwithdrawalmay
e related tobodyattentional processes, butmorphine is associated
ith both pleasant and unpleasant body sensations (Jasinski and
reston, 1986), and naloxone-precipitated withdrawal is associ-
tedwithgenerally distressing somatic symptoms (Heishmanet al.,
990).
Overall, acute opioid withdrawal was found to be associated
ith increased activity in reward-processing regions. As a model of
cute opioid withdrawal effects in healthy individuals, the results
f this fMRI study ﬁt well with existing literature. While no stud-
es have observed the effects of naloxone-precipitated withdrawal
n healthy individuals treated with morphine, several studies have
xamined the acute effects of morphine on humans. In most cases,
nd as expected, those studies show the regions identiﬁed to be
ffected in the opposite direction by morphine administration
Khalili-Mahani et al., 2012; London et al., 1990). The use of ALFF
ay therefore be a valid method for assessing correlates of acute
pioid withdrawal in the human brain.
.2. Major ﬁndings: Effects of ondansetron pretreatment on
pioid withdrawal and resting-state activity during withdrawal
The second aim of this study was to determine if ondansetron
retreatment would reduce withdrawal symptoms, as well as theendence 153 (2015) 314–322
neural response to naloxone. Ondansetron, a 5-HT3 receptor antag-
onist, has shown promise as an agent that can reduce adverse
opioid effects such as withdrawal, tolerance, and dependence
(Chu et al., 2009). It was, therefore, hypothesized that pretreat-
ment with ondansetron would reduce both the behavioral signs
and neural response to withdrawal. That hypothesis, however,
was largely unsupported by the results. No effect of ondansetron
pretreatment was observed on either self-reported withdrawal
severity or resting-state neural activity. Also, while ondansetron
was associated with fewer objective withdrawal signs at ﬁve min-
utes post-naloxone, those differences were not observed at 15min
post-naloxone.While the sample sizewas small andmay have con-
tributed to the lack of signiﬁcant ﬁndings, the effect sizes were
small (OOWS Cohen’s d=0.18; SOWS Cohen’s d=0.42) and would
require a large number of participants for statistical sensitivity.
Effect sizes were also calculated for the effects of ondansetron
on ALFF in the clusters showing the greatest magnitudes of ALFF
change – left caudate head Cohen’s d=0.004; left pre/postcentral
gyrus Cohen’s d=0.14. It is also noted that only healthy individu-
als with very limited opioid exposure were included in the present
study, and results may be different if obtained from a clinical pop-
ulation with longer-term opioid usage.
4.3. Limitations
A number of limitations and caveats should be considered
in the interpretation of this study. First, the sample size of this
study was small, due to the difﬁculty of the protocol and discom-
fort experienced by participants. While the repeated-sessions and
within-person analytic approach mitigate some problems associ-
ated with small sample size, larger sample-size studies are needed
before conclusions can be made. A height threshold and a cluster-
extent threshold were used in order to increase conﬁdence in the
results; however, the combined thresholds may have precluded
detection of small potential areas of interest, such as the ventral
tegmental area andperiaqueductal gray. A-priori regionsof interest
may also be used to circumvent the problems of multiple compar-
isons.
Second, it is difﬁcult to know whether the neural changes
observed in this study were related to acute withdrawal, nalox-
one administration alone, or a combination of both as naloxone
has been shown to elicit signal changes in similar regions (Borras
et al., 2004).Moreover, the lack of a ‘non-withdrawal’ baseline scan
in which no treatment was administered further complicates the
interpretation of the ﬁndings. Although OOWS and SOWS scores
from these healthy participants indicated a fairly mild withdrawal
experience, ALFF signal changes within several reward-related
regions (e.g., bilateral inferior orbital frontal gryi)were signiﬁcantly
associated with objective and subjective withdrawal symptoms,
suggesting that some neural changes may have been associated
with the withdrawal experience itself. Changes in connectivity to
these regions have also been associated with opioid dependence
(Upadhyay et al., 2010). However, future research is needed delin-
eate aspects of the response tonaloxone administration and further
disentangle the effects of naloxone and withdrawal.
A third limitation is the potential presence of physiological
noise. To maximize participant safety, vital signs (full EKG, oxy-
gen saturation, and blood pressure) were monitored with medical
grade equipment instead of the scanner-integrated physiological
recording sensors. Therefore, physiological noise correction could
not be applied to the data. Opioid withdrawal is known to be
associated with both heart rate and respiratory changes, which
can impact BOLD-related activity. However, heart rate and res-
piration likely had minimal impact on the results as vital signs
remained unchanged after naloxone administration and the poten-
tial impact of physiological noise was partially mitigated by using
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and-limiting the window of frequencies in the ALFF approach.
evertheless, the effects of changing hemodynamics cannot be
ompletely ruled out when interpreting the ﬁndings. It should
lso be noted that conventional physiological noise correction
lgorithms may also substantially remove true signal in pharma-
ological fMRI studies (Khalili-Mahani et al., 2013).
A similar index of LFO amplitude – fractional ALFF (fALFF) – is
eﬁned as the ratio of the power within the low frequency range
o that of the entire frequency range, and provides information
n the relative amplitude that resides in the low frequencies (Zou
t al., 2008). Although recent studies have suggested that the fALFF
pproach can be more sensitive to detecting spontaneous brain
ctivity in certain areas (Zou et al., 2008), we could not use the
ALFF approach as physiological data were collected separately
rom scanning. Therefore, artifactual signals from cardiac and res-
iratory processes may be present in the overall frequency range
nd this can affect the accuracy of fALFF results. Furthermore, ALFF
as been shown to demonstrate higher test-retest reliability in
ray matter regions (Zuo et al., 2010); therefore, ALFF was con-
idered the most appropriate index for these data. Incorporating
imultaneous measurement of cardiac and respiratory processes
n future studies may allow both ALFF and fALFF results to be
resented.
Finally, it cannot be assumed that this opioid withdrawal
odel is generalizable to long-term opioid users. Withdrawal
fter an acute exposure to morphine may be quite different
rom withdrawal after months or years of opioid use. Naloxone
ppeared to have minimal impact on subjective and objective
pioid withdrawal symptoms; however, those withdrawal-related
xperiences and behaviors would be expected to be more pro-
ounced in long-term opioid users.
.4. Future research and conclusion
While this research presents a preliminary investigation of
egional changes in neural activity during acute opioidwithdrawal,
t is more difﬁcult to understand the function of these changes and
he implications for treating opioid withdrawal. In addition to the
bovementioned limitations, the authors have some suggestions
or future work. Although creating an additional burden to exper-
menters and participants, it is recommended that experimenters
ishing to use this protocol run a pilot for each participant in a
ock scanner as it helps ensure that the participant is suitable
or the real scanner environment. Mock scanning also controls for
rder effects by exposing all participants to the protocol before
reatment randomization. Future studies should incorporate the
ollection of baseline resting state data prior to pretreatment to
nable comparisons with a non-withdrawal condition, as well as
aloxone only (no opioid administration) condition to allow for
ore robust conclusions to be made on the effects naloxone and
ithdrawal. Furthermore, experimenters should capture as many
ehavioral and self-report variables aspossible inorder todelineate
hanges that are critical to the behavioral, motivational, sensory,
nd other aspects of the withdrawal experience.
This study aimed to characterize brain activity associated acute
pioid withdrawal using fMRI. Naloxone administration was asso-
iated with increased neural activity in several reward-association
nd reward-prediction regions, such as the caudate, pregenual
ingulate, and orbitofrontal gryus. However, pretreatment with
ndansetron did not appear to have any appreciable effects on
elf-reported withdrawal symptoms or resting state neural activ-
ty. Future research is needed to validate these ﬁndings and further
evelopment of this model may render it suitable for assessing the
mpact of withdrawal and improve the understanding of medica-
ions and treatments intended tomitigatewithdrawal experiences.endence 153 (2015) 314–322 321
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